Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293111 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00293111 is a Phase 2 study that was terminated before completion, run by Cephalon. The registered enrollment target is 30 participants.
The verdict
NCT00293111, a Phase 2 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)
Interventions
- DRUG SDX-101 (R-Etodolac)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293111
The ClinicalTrials.gov registry entry for NCT00293111 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SDX-101 (R-Etodolac) is the first listed.
NCT00293111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293111 about?
NCT00293111 is a clinical study titled "Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)". An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)
What is the current status of trial NCT00293111?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-02.
What interventions are being tested in trial NCT00293111?
The interventions under investigation include: SDX-101 (R-Etodolac) (DRUG).
Who is sponsoring clinical trial NCT00293111?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.